Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 937 • 2019 ACR/ARP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study
Désirée van der Heijde¹, Lianne Gensler ², Atul Deodhar ³, Xenofon Baraliakos ⁴, Denis Poddubnyy ⁵, Alan Kivitz ⁶, Marga Oortgiesen ⁷, Dominique Baeten ⁸, Nadine Goldammer ⁹, Jason Coarse ⁷, MK Farmer ⁷ and Maxime Dougados ¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²University San Francisco California, San Francisco, CA, ³Oregon Health & Science University, Portland, OR, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ⁸UCB Pharma, Brussels, Belgium, Brussels, ⁹UCB Pharma, Monheim, Germany, Monheim, Germany, ¹⁰Cochin Hospital, Paris, France
Background/Purpose: The monoclonal antibody bimekizumab potently and selectively neutralizes both IL-17A and IL-17F. We report the 48-week efficacy and safety of bimekizumab in patients (pts)…
Abstract Number: 1536 • 2019 ACR/ARP Annual Meeting
A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Francisco Ramírez-Valle¹, Mary Adams ¹, Lisa Beebe ², Jian Chen ¹, Claudio Chuaqui ¹, Jamie Connarn ¹, Alan Corin ¹, Karen Dingley ¹, J. Michael Ellis ¹, Rajula Gaur ¹, Lawrence Hamann ¹, John Malona ¹, Kofi Mensah ¹ and Maria Palmisano ¹, ¹Celgene Corporation, Summit, NJ, ²Celgene Corporation, Cambridge, MA
Background/Purpose: Post-transcriptional control of cytokine and chemokine gene expression is an important checkpoint during inflammation. The MAPKAPK2 (MK2) pathway in particular is critical in regulating…
Abstract Number: 598 • 2019 ACR/ARP Annual Meeting
Identification of Potential Risk Factors for Spinal Structural Damage in Chinese Patients with Ankylosing Spondylitis
Weiping Kong¹, Caroline Jefferies ², Tom Learch ², Feng Zhu ¹, Nan Zhang ¹, Dier Jin ¹, Yingze Zhang ¹, Qingwen Tao ¹, Xiaoping Yan ¹, Michael Weisman ³ and Mariko Ishimori ², ¹China-Japan Friendship Hospital, Beijing, China (People's Republic), ²Cedars-Sinai Medical Center, Los Angeles, CA, ³David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Spinal structural damage can lead to physical dysfunction and decline of spinal mobility in patients with ankylosing spondylitis (AS). Although great progress has been…
Abstract Number: 1010 • 2019 ACR/ARP Annual Meeting
IL-17A Induces Distinct Functional Differences Between Two Novel Mesenchymal Stem Cell Populations Identified at the Human Enthesis
Tobias Russell¹, Abdulla Watad ², Charlie Bridgewood ³, Almas Khan ⁴, Abhay S Rao ⁴, Peter Loughenbury ⁴, Peter Milner ⁴, Robert Dunsmuir ⁴, Thomas Baboolal ³, Elena Jones ⁵, Richard Cuthbert ¹ and Dennis McGonagle ⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM)University of Leeds, Leeds, England, United Kingdom, ²Department of Medicine “B”, Zabludowicz Center for Autoimmune Diseases Sheba Medical Center, Ramat-Gan, Israel, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM)University of Leeds, Leeds, United Kingdom, ⁴Leeds Teaching Hospitals NHS Trust, Leeds, ⁵University of Leeds, Leeds, England, United Kingdom, ⁶University of Leeds, Leeds, United Kingdom
Background/Purpose: Ankylosing spondylitis (AS) is associated with entheseal inflammation and new bone formation. Resident populations of lymphocytes have been identified at the enthesis that on…
Abstract Number: 1542 • 2019 ACR/ARP Annual Meeting
Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Prospective Observational Registry
Proton Rahman ¹, Derek Haaland ², Dalton Sholter ³, Michael Starr ⁴, Arthur Karasik ⁵, Michelle Teo ⁶, Sanjay Dixit ⁷, Ariel Masetto ⁸, Anna Jaroszynska ⁹, Pauline Boulos ⁷, Emmanouil Rampakakis ¹⁰, Meagan Rachich ¹¹, Odalis Asin-Milan ¹¹, Allen Lehman ¹¹ and Francois Nantel¹¹, ¹Memorial University, Newfoundland, NL, Canada, ²Waterside Clinic, Barrie, ON, Canada, ³Rheumatology Associates, Edmonton, AB, Canada, ⁴Montreal General Hospital, Montreal, QC, Canada, ⁵., Toronto, ON, Canada, ⁶Balfour Medical Clinic, Penticton, BC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸Université de Sherbrooke, Sherbrooke, QC, Canada, ⁹., Oakville, ON, Canada, ¹⁰JSS Medical Research, Montreal, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trial and usually varies over time. The purpose…
Abstract Number: L13 • 2018 ACR/ARHP Annual Meeting
Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial
Xenofon Baraliakos¹, Jürgen Braun², Atul A. Deodhar³, Denis Poddubnyy⁴, Alan J. Kivitz⁵, Hasan Tahir⁶, Filip van Den Bosch⁷, Evie Maria Delicha⁸, Zsolt Talloczy⁹ and Anke Fierlinger⁹, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, and Ruhr University Bochum, Herne, Germany, Herne, Germany, ³Oregon Health & Science University, Portland, Portland, OR, ⁴Rheumatology, Campus Benjamin Franklin Charité – Universitätsmedizin, Germany and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁵Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁶Whipps Cross University Hospital, Barts Health NHS Trust, London, United Kingdom, ⁷Rheumatology, Universitair Ziekenhuis, Ghent, Belgium, Gent, Belgium, ⁸Novartis Pharma AG, Basel, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States, East Hanover, NJ
Background/Purpose: Clinical evaluation of efficacy and safety for long-term treatment for ankylosing spondylitis (AS) is important for treatment decision-making. Secukinumab (SEC), a fully human mAb…
Abstract Number: 660 • 2018 ACR/ARHP Annual Meeting
Progression of Radiographic Sacroiliitis in Patients with Axial Spondyloarthritis from the Assessment of Spondyloarthritis International Society Cohort on Central Reading – Five-Year Data
Mikhail Protopopov¹, Fabian Proft¹, Alexandre Sepriano^2,3, Robert B.M. Landewé^4,5, Désirée van der Heijde², Joachim Sieper¹, Martin Rudwaleit^6,7 and Denis Poddubnyy^1,8, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal, ⁴Zuyderland Medical Center, Heerlen, Netherlands, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands, ⁶Charité Universitätsmeidzin Berlin, Berlin, Germany, ⁷Rheumatology, Klinikum Bielefeld Rosenhöhe, Berlin, Germany, ⁸German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: It is known that radiographic progression of sacroiliitis in axial spondyloarthritis (axSpA) is quite slow, with only few predictors of such progression identified. An…
Abstract Number: 1189 • 2018 ACR/ARHP Annual Meeting
Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean Perspective
Dam Kim¹, Hyojin Kim², Seongha Cho² and Min-Chan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea, Republic of (South), ²Patient Access Team, Novartis Korea, Seoul, Korea, Republic of (South)
Secukinumab versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean PerspectiveDam Kim1, Hyojin Kim2, SeongHa Cho2, Min-Chan Park11Division of…
Abstract Number: 1830 • 2018 ACR/ARHP Annual Meeting
Role of BMP2 in Entheseal Bone Formation in Inflammatory Arthritis
Yukiko Maeda¹, Jozsef Karman² and Ellen M. Gravallese³, ¹Medicine, University of Massachusetts Medical School, Worcester, MA, ²Abbvie Bioresearch Center, Worcester, MA, ³Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Spondyloarthritis (SpA) is common, with a prevalence of ~1% in the United States. Patients with SpA suffer from pain and disability due to inflammation…
Abstract Number: 2597 • 2018 ACR/ARHP Annual Meeting
The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Patient Reported Outcomes in Axial Spondyloarthritis; A Systematic Literature Review and a Call for Action
Santiago Rodrigues Manica^1,2, Joana Leite Silva³, Ana Rita Machado⁴, Constança Coelho⁵, Joana Duarte⁶, Elsa Vieira-Sousa⁷, José Tavares Costa⁸ and Fernando Pimentel-Santos^1,2, ¹CEDOC, NOVA Medical School, Lisbon, Portugal, ²Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ³Serviço de Reumatologia da Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁴Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, ⁵Genetics Laboratory, Institute of Environmental Health, Lisbon School of Medicine, University of Lisbon, Lisbon, Portugal, ⁶Medical Department, Novartis Pharma, Pharmaceutical products, Oeiras, Portugal, ⁷Rheumatology Department, CAML, Lisbon, Portugal, Lisbon, Portugal, ⁸Rheumatology Department, ULSAM, Ponte de Lima, Portugal, Ponte de Lima, Portugal
Background/Purpose: Patient reported outcomes (PROs) have gained relevance in the evaluation of axial SpA (axSpA), as they convey a more objective patient perspective. The concept…
Abstract Number: 670 • 2018 ACR/ARHP Annual Meeting
Low Rate of Spinal Radiographic Progression over 2 Years in Ankylosing Spondylitis Patients Treated with Secukinumab: A Historical Cohort Comparison
Jürgen Braun¹, Hildrun Haibel², Manouk de Hooge³, Robert B.M. Landewé⁴, Martin Rudwaleit⁵, Todd Fox⁶, Aimee Readie⁷, Hanno Richards⁶, Brian Porter⁸, Ruvie Martin⁷, Denis Poddubnyy⁹, Joachim Sieper¹⁰ and Désirée van der Heijde¹¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Charité Universitätmedizin Berlin, Berlin, Germany, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Maastricht Univ Medical Center, Maastricht, Netherlands, ⁵Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁹Charité Universitätsmedizin Berlin, Berlin, Germany, ¹⁰Charité Universitätsmeidzin Berlin, Berlin, Germany, ¹¹Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Secukinumab, a fully human monoclonal antibody that neutralizes IL-17A, improved signs and symptoms of ankylosing spondylitis (AS) in patients (pts) in the MEASURE 1…
Abstract Number: 1224 • 2018 ACR/ARHP Annual Meeting
High Rates of Conversion and Reversion of Tuberculosis Screening Assays in Rheumatic Patients during Long Term Biologic Treatment
Konstantinos Thomas¹, Anastasia Makris¹, Christina Tsalapaki¹, Argyro Lazarini¹, Kalliopi Klavdianou¹, Katerina Antonatou¹, Christos Koutsianas¹, Chrisoula Hatzara¹, Emilia Hadziyannis¹ and Dimitrios Vassilopoulos², ¹Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ²Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General HospitalMedicine, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Background/Purpose: Baseline screening for tuberculosis (TB) with tuberculin skin testing (TST) and/or interferon-gamma release assays (IGRAs) is recommended for all rheumatic patients starting biologic DMARDs…
Abstract Number: 1831 • 2018 ACR/ARHP Annual Meeting
Intestinal Inflammatory Regulation in Murine and Human Spondyloarthropathy Requires High-Affinity T Cell Receptor-Zeta Chain-Associated Protein (ZAP)70-Mediated Runt-Related Transcription Factor (Runx)3 Activity
Zaied Ahmed Bhuyan¹, M. Arifur Rahman², Muralidhara Maradana¹, Ahmed Mehdi³, Giuliana Guggino⁴, Paul Leo⁵, Linda Rehaume¹, Matthew Brown⁵, Francesco Ciccia⁴ and Ranjeny Thomas¹, ¹The University of Queensland Diamantina Institute, Brisbane, Australia, ²Translational Research Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, ³Diamantina Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Rheumatology Unit, University of Palermo, Palermo, Italy, ⁵Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia
Background/Purpose: Loss of function RUNX3 variants are associated with ankylosing spondylitis (AS) risk but the mechanism is unknown. Disturbances in immune regulation, intestinal microbial dysbiosis…
Abstract Number: 2617 • 2018 ACR/ARHP Annual Meeting
Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
Arvind Chopra¹, Nagnath Khadke², Manjit Saluja³, Toktam Kainifard⁴ and Anuradha Venugopalan⁵, ¹Center for Rheumatic Diseases, Pune, India, ²Rheumatolgy, Consultant, Pune, India, ³Rheumatology, Research Co-ordinator, Pune, India, ⁴Rheumatology, Consultant research and Dietitian, Tehran, Iran (Islamic Republic of), ⁵Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India
Background/Purpose: On regulatory approval in India, challenging socioeconomics and infection prone scenario compelled us to seek prolonged effectiveness of short term anti-TNF therapeutic regimen (Chopra…
Abstract Number: 672 • 2018 ACR/ARHP Annual Meeting
Activation of NLRP3 Inflammasomes in Peripheral Blood Mononuclear Cells of Patients with Ankylosing Spondylitis
Seong-Kyu Kim¹ and Jung-Yoon Choe², ¹Rheumatology, Daegu Catholic University School of Medicine, Daegu, Korea, Republic of (South), ²Department of Internal Medicine, Catholic university of Daegu School of Medicine, Daegu, Korea, Republic of (South)
Background/Purpose: NLRP3 inflammasome is a molecular platform triggering activation of inflammatory cytokines including interleukin-1b (IL-1b). This study aimed to assess the expression of NLRP3 inflammasome…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.